S-1 Versus 5-FU Bolus in Metastatic Pancreatic Cancer Patients Previously Treated With Gemcitabine-Based Regimen
Stopped Following the termination of development and commercialization agreement for S-1 with Taiho Pharmaceutical
Conditions
- Pancreatic Neoplasm
- Neoplasm Metastasis
Interventions
- DRUG: S-1
- DRUG: 5-Fluorouracil
Sponsor
Sanofi
Collaborators